Positive Interim Data Shows Genentech's Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy
September 23, 2026
September 23, 2026
SOUTH SAN FRANCISCO, California, Sept. 23 -- Genentech, a member of the Roche Group, issued the following news release:
* * *
Positive Interim Data Shows Genentech's Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)
* In the Phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential
< . . .
* * *
Positive Interim Data Shows Genentech's Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)
* In the Phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential
< . . .